A New Promise for Obesity Treatment?
Researchers have been investigating retatrutide, a groundbreaking dual-agonist targeting both GLP-1 and GIP receptors. This compound demonstrates remarkable potential in supporting sustained weight reduction . Early research findings suggest that retatrutide may offer enhanced efficacy compared t